Just last week, The American College of Cardiology Foundation and American Heart Association Task Force on Practice Guidelines issued its new guidelines for the diagnosis and management of patients with stable ischemic heart disease.
For improving the management of patients with chronic stable angina, a proprietary non-invasive cardiology treatment patented by Vasomedical Inc. is enhancing external counter pulsation or EECP Therapy and now retains the same IIb class of recommendation (COR) rating that it received in the ACC/AHA 2002 guideline update.
For level of evidence (LOE), EECP Therapy was given a B rating. A class IIb rating, according to the guidelines, maintains that procedures and treatments may be considered for patients. Although further registry data would be helpful, additional studies with broad objectives are needed. This classification finds that the benefits of treatments are greater than or equal to the risk of treatment.
"We believe that the 2012 Guideline clearly characterizes EECP Therapy as the gold standard of ECP treatments, since other forms of ECP treatments were not even considered for a ranking,” said Dr. Jun Ma, president and chief executive officer of Vasomedical Inc,, in a statement.
Ma added that for ischemic heart disease he is pleased that this classification reinforces EECP Therapy's position as the preeminent, non-invasive treatment. In the Unites States, EECP Therapy has been offered to hundreds of thousands of patients in multiple treatment centers and hospitals throughout the past decade.
From many different studies including randomized controlled trials published in peer reviewed journals combines a wealth of data and has received countless testimonials in regards to the improvement to patients' overall quality of life.
Edited by
Jamie Epstein
